Neuroblastoma cells isolated from bone marrow metastases contain a naturally enriched tumor-initiating cell

被引:138
作者
Hansford, Loen M.
Mckee, Amy E.
Zhang, Libo
George, Rani E.
Gerstle, J. Ted
Thorner, Paul S.
Smith, Kristen M.
Look, A. Thomas
Yeger, Herman
Miller, Freda D.
Irwin, Meredith S.
Thiele, Carol J.
Kaplan, David R.
机构
[1] Hosp Sick Children, Cell Biol Program, Toronto, ON M5G 1L7, Canada
[2] Hosp Sick Children, Dept Surg, Toronto, ON, Canada
[3] Hosp Sick Children, Dev & Stem Cell Biol Program, Toronto, ON, Canada
[4] Hosp Sick Children, Div Haematol Oncol, Toronto, ON, Canada
[5] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada
[6] Univ Toronto, Dept Mol & Med Genet, Toronto, ON, Canada
[7] NIH, Pediat Oncol Branch, Bethesda, MD 20892 USA
[8] Dana Farber Canc Inst, Dept Pediat Hematol & Oncol, Boston, MA USA
关键词
D O I
10.1158/0008-5472.CAN-07-0718
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Neuroblastoma is a heterogeneous pediatric tumor thought to arise from the embryonic neural crest. Identification of the cell responsible for propagating neuroblastomas is essential to understanding this often recurrent, rapidly progressing disease. We have isolated and characterized putative tumor-initiating cells from 16 tumors and bone marrow metastases from patients in all neuroblastoma risk groups. Dissociated cells from tumors or bone marrow grew as spheres in conditions used to culture neural crest stem cells, were capable of self-renewal, and exhibited chromosomal aberrations typical of neuroblastoma. Primary spheres from all tumor risk groups differentiated under neurogenic conditions to form neurons. Tumor spheres from low-risk tumors frequently formed large neuronal networks, whereas those from high-risk tumors rarely did. As few as 10 passaged tumor sphere cells from aggressive neuroblastoma injected orthotopically into severe combined immunodeficient/Beige mice formed large neuroblastoma tumors that metastasized to liver, spleen, contralateral adrenal and kidney, and lung. Furthermore, highly tumorigenic tumor spheres were isolated from the bone marrow of patients in clinical remission, suggesting that this population of cells may predict clinical behavior and serve as a biomarker for minimal residual disease in high-risk patients. Our data indicate that high-risk neuroblastoma contains a cell with cancer stem cell properties that is enriched in tumor-initiating capacity. These cells may serve as a model system to identify the molecular determinants of neuroblastoma and to develop new therapeutic strategies for this tumor.
引用
收藏
页码:11234 / 11243
页数:10
相关论文
共 48 条
[1]  
AKASHI T, 1994, VIRCHOWS ARCH, V425, P399
[2]   Prospective identification of tumorigenic breast cancer cells [J].
Al-Hajj, M ;
Wicha, MS ;
Benito-Hernandez, A ;
Morrison, SJ ;
Clarke, MF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) :3983-3988
[3]   Detecting minimal residual disease in neuroblastoma patients - the present state of the art [J].
Beiske, K ;
Ambros, PF ;
Burchill, SA ;
Cheung, IY ;
Swerts, K .
CANCER LETTERS, 2005, 228 (1-2) :229-240
[4]   Limitations in the ability of NB84 to detect metastatic neuroblastoma cells in bone marrow [J].
Bomken, S. N. ;
Redfern, K. ;
Wood, K. M. ;
Reid, M. M. ;
Tweddle, D. A. .
JOURNAL OF CLINICAL PATHOLOGY, 2006, 59 (09) :927-929
[5]   Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell [J].
Bonnet, D ;
Dick, JE .
NATURE MEDICINE, 1997, 3 (07) :730-737
[6]  
Bozzi F, 2006, ANTICANCER RES, V26, P3281
[7]   Neuroblastoma: Biological insights into a clinical enigma [J].
Brodeur, GM .
NATURE REVIEWS CANCER, 2003, 3 (03) :203-216
[8]   DETECTION OF NEUROBLASTOMA-CELLS IN BONE-MARROW USING GD2 SPECIFIC MONOCLONAL-ANTIBODIES [J].
CHEUNG, NKV ;
VONHOFF, DD ;
STRANDJORD, SE ;
COCCIA, PF .
JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (03) :363-369
[9]   CNS recurrence following CD34+ peripheral blood stem cell transplantation in stage 4 neuroblastoma [J].
Choi, HS ;
Koh, SH ;
Park, ES ;
Shin, HY ;
Ahn, HS .
PEDIATRIC BLOOD & CANCER, 2005, 45 (01) :68-71
[10]  
Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126